Human CellExp™ Vasorin / VASN, Human recombinant | P1134

Vasorin (VASN),a single-pass type I membrane protein, is also known as protein slit-like 2 and SLITL2, which contains one EGF-like domain, ten LRR (leucine-rich) repeats, one LRRCT domain and one LRRNT domain. VASN is expressed at highest levels in aorta, at intermediate levels in kidney and placenta and at lowest levels in brain, heart, liver, lung and skeletal muscle. VASN can interact selectively and non-covalently with TGF-beta, transform growth factor beta, a multifunctional peptide that controls proliferation, differentiation and other functions in many cell types. In general, VASN may act as an inhibitor of TGF-beta signaling.

P1134 | Human CellExp Vasorin / VASN Human recombinant DataSheet

Biomolecule/Target: VASN

Synonyms: VASN, SLITL2, Vasorin

Alternates names: Hexokinase type I, Brain form hexokinase, HK1.

Taglines: Inhibitor of TGF-beta signaling.

NCBI Gene ID #: 3098

NCBI Gene Symbol: HXK1

Gene Source: Human

Accession #: P19367

Recombinant: Yes

Source: E. coli

Purity by SDS-PAGEs: 90%

Assay: SDS-PAGE

Purity: N/A

Assay #2: N/A

Endotoxin Level: < 1.0 EU per/g

Activity (Specifications/test method): N/A

Biological activity: Specific activity is 7-8 units/ml obtained by measuring the increase of NADPH in absorbance at 340 nm resulting from the reduction of NADP.

Results:

Binding Capacity: N/A

Unit Definition: N/A

Molecular Weight: 104.6 kDa

Concentration: N/A

Appearance: Lyophilized

Physical form description: Lyophilized from 0.22 m filtered solution in PBS, pH7.4. Normally Trehalose is added as protectant before lyophilization.

Reconstitution Instructions: N/A

Amino acid sequence: MGSSHHHHHH SSGLVPRGSH MIAAQLLAYY FTELKDDQVK KIDKYLYAMR LSDETLIDIM TRFRKEMKNG LSRDFNPTAT VKMLPTFVRS IPDGSEKGDF IALDLGGSSF RILRVQVNHE KNQNVHMESE VYDTPENIVH GSGSQLFDHV AECLGDFMEK RKIKDKKLPV GFTFSFPCQQ SKIDEAILIT WTKRFKASGV EGADVVKLLN KAIKKRGDYD ANIVAVVNDT VGTMMTCGYD DQHCEVGLII GTGTNACYME ELRHIDLVEG DEGRMCINTE WGAFGDDGSL EDIRTEFDRE IDRGSLNPGK QLFEKMVSGM YLGelVRLIL VKMAKEGLLF EGRITPELLT RGKFNTSDVS AIEKNKEGLH NAKEILTRLG VEPSDDDCVS VQHVCTIVSF RSANLVAATL GAILNRLRDN KGTPRLRTTV GVDGSLYKTH PQYSRRFHKT LRRLVPDSDV RFLLSESGSG KGAAMVTAVA YRLAEQHRQI EETLAHFHLT KDMLLEVKKR MRAEMELGLR KQTHNNAVVK MLPSFVRRTP DGTENGDFLA LDLGGTNFRV LLVKIRSGKK RTVEMHNKIY AIPIEIMQGT GEELFDHIVS CISDFLDYMG IKGPRMPLGF TFSFPCQQTS LDAGILITWT KGFKATDCVG HDVVTLLRDA IKRREEFDLD VVAVVNDTVG TMMTCAYEEP TCEVGLIVGT GSNACYMEEM KNVEMVEGDQ GQMCINMEWG AFGDNGCLDD IRTHYDRLVD EYSLNAGKQR YEKMISGMYL GEIVRNILID FTKKGFLFRG QISETLKTRG IFETKFLSQI ESDRLALLQV RAILQQLGLN STCDDSILVK TVCGVVSRRA AQLCGAGMAA VVDKIRENRG LDRLNVTVGV DGTLYKLHPH FSRIMHQTVK ELSPKCNVSF LLSEDGSGKG AALITAVGVR LRTEASS